<DOC>
	<DOCNO>NCT00121459</DOCNO>
	<brief_summary>The purpose trial determine whether use diaphragm lubricant get reduce woman 's risk acquire HIV infection .</brief_summary>
	<brief_title>Effectiveness Diaphragm HIV Prevention</brief_title>
	<detailed_description>This multi-site randomized , control trial measure effectiveness diaphragm prevent heterosexual acquisition HIV infection among woman . This Phase III study power detect effectiveness ( biological efficacy combine adherence ) 33 percent . Women South Africa Zimbabwe ( N=4,500 ) risk contract HIV invite participate follow 24 month , total study duration 4 year . All woman receive safer-sex counseling , free male condom diagnosis treatment sexually transmit infection ( STIs ) . Half participant randomly select receive Ortho All-Flex latex diaphragm Replens lubricant gel . We assess whether woman use diaphragms lubricant gel lower rate HIV STI infection non-diaphragm gel counterpart . Additionally , investigate long-term acceptability diaphragm study population .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Psyllium</mesh_term>
	<mesh_term>Calcium polycarbophil</mesh_term>
	<criteria>Age 18 49 year old Sexually active ( coital frequency least four time per month average ) HIV negative base test within two week prior enrollment Chlamydia trachomatis Neisseria gonorrhoeae negative base test within 30 day prior enrollment positive , complete treatment enrollment Have healthy cervix , assess nakedeye speculum exam enrollment Planning live study area next 24 month Willing randomly assign either use use latex diaphragm lubricant gel participation study , follow protocol , include test HIV STIs Willing able give inform consent Known sensitivity allergy latex History TSS ( suggest current labeling diaphragm use ) Currently pregnant , desire become pregnant next two year No cervix ( total hysterectomy ) Refuses treatment diagnose suspected current STI and/or reproductive tract infection require treatment enrollment Within six week pelvic surgery last pregnancy outcome time screen enrollment Presence clinically apparent lesion ( ) epithelial disruption enrollment ( may enroll lesion ( ) heal , otherwise eligible ) Injected illicit drug 12 month prior screen enrollment Blood transfusion receive blood product 3 month prior screen enrollment Unable unwilling insert diaphragm correctly Participation clinical trial ( include vaginal product barrier contraceptive ) . Verification compare participant list concurrently run research study may conduct necessary . Unable speak English , Zulu , Shona , Sotho Other condition , opinion investigator , would constitute contraindication participation study would compromise ability comply study protocol , major psychiatric disorder</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Diaphragm</keyword>
	<keyword>HIV prevention</keyword>
	<keyword>Southern/South Africa , Zimbabwe</keyword>
	<keyword>female-controlled method</keyword>
	<keyword>Replens</keyword>
	<keyword>STI prevention</keyword>
	<keyword>HIV Seronegativity</keyword>
</DOC>